StockNews.com Initiates Coverage on Aspira Women’s Health (NASDAQ:AWH)

Analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners dropped their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Down 1.6 %

NASDAQ AWH opened at $0.90 on Friday. The company has a 50 day moving average price of $0.89 and a 200 day moving average price of $1.61. The firm has a market cap of $14.46 million, a PE ratio of -0.62 and a beta of 1.47. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $5.65.

Aspira Women’s Health (NASDAQ:AWH) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to analyst estimates of $2.60 million. During the same period in the prior year, the business posted ($0.28) EPS. On average, equities research analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.